Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs

Chinese Journal of Digestive Diseases

Volumn 7, Issue 1, 2006, Pages 1-6

  Hilmi, I ^a   Goh, K L ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Chemoprevention; Colorectal cancer; Cyclooxygenase 2 inhibitors; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; FOLINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; PROSTAGLANDIN; PROSTANOID; ROFECOXIB; SULINDAC;

ANGIOGENESIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON POLYPOSIS; COLON RESECTION; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG MECHANISM; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HUMAN; INHIBITION KINETICS; KIDNEY DISEASE; KIDNEY FAILURE; PEPTIC ULCER; PRIMARY PREVENTION; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS; REVIEW; SECONDARY PREVENTION; TREATMENT FAILURE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOPREVENTION; CLINICAL TRIALS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; HUMANS;

EID: 33644922063     PISSN: 14439611     EISSN: 14439573     Source Type: Journal    
DOI: 10.1111/j.1443-9573.2006.00236.x     Document Type: Review

References (64)

1. Boyle P, Langman JS. ABC of colorectal cancer: Epidemiol. BMJ 2000; 321: 805-8.
2. Lee HP, Chia KS, Shanmugaratnmam K. Cancer incidence in Singapore 1983-1987. In: Parkin DM, Muir CS, When SL, Gao YT, Ferlay J, Powell J, eds. Cancer Incidence in Five Continents, Vol. VI. Lyon, IARC Scientific Publications 120; 1992.
3. Lee HP, Chia KS, Seow ALH, Shanmugaratnmam K. Cancer incidence in Singapore 1988-1992. In: Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer Incidence in Five Continents, Vol. VII. Lyon, IARC Scientific Publications 143; 1997.
4. Ochikubo S, Watari S, Fukuhara T, Dohy H, Akiba S, Mabuchi K. Cancer incidence in Japan, Hiroshima City 1981-85. In: Parkin DM, Muir CS, When SL, Gao YT, Ferlay J, Powell J, eds. Cancer Incidence in Five Continents, Vol. VI. Lyon, IARC Scientific Publications 120; 1992.
5. Sanada K, Kimura S, Fukuhara T, Fujita Y, Mabuchi K. Cancer incidence in Japan, Hiroshima City 1986-90. In: Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer Incidence in Five Continents, Vol. VII. Lyon: IARC Scientific Publications 143; 1997.
6. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer: Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-8.
7. Hardcastle JD, Chamberlain JO, Robinson MHE et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-7.
8. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study screening of colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-71.
9. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal carcinoma by screening for fecal occult blood. N Engl J Med 1993; 328: 1365-71.
10. Sung JJ, Chan FK, Leung WK et al. Screening for colorectal cancer in Chinese: Comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology 2003; 124: 608-14.
11. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-6.
12. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16 737-40.
13. Kraemer SA, Meade EA, DeWitt DL. Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch Biochem Biophys 1992; 293: 391-400.
14. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002; 3: 166-74.
15. Watson AJ. Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histopathology 1998; 13: 591-7.
16. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998; 95: 681-6.
17. Wu GD. A nuclear receptor to prevent colon cancer. N Engl J Med 2000; 342: 651-3.
18. Tsujii M, Kwano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
19. Chan TA. Cyclooxygenase inhibition and mechanisms of colorectal cancer prevention. Curr Cancer Drug Targets 2003; 3: 455-63.
20. Eberhart CE, Coffey RJA, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
21. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000; 1470: M69-78.
22. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-12.
23. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83-7.
24. Hune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-404.
25. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer and polyps of the large bowel. Cancer 1993; 72: 1171-7.
26. Peleg II, Mailbach C, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154: 394-9.
27. Sorensen HT, Friis S, Norgard B et al. Risk of cancer in a large cohort of nonaspirin NSAID users: A population-based study. Br J Cancer 2003; 88: 1687-92.
28. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003; 88: 684-8.
29. Strul H, Arber N. Non-steroidal anti-inflammatory drugs and selective apoptotic anti-neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins. Isr Med Assoc J 2000; 2: 695-702.
30. Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003; 14: 915-22.
31. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database. BMJ 2000; 320: 1642-6.
32. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82: 1364-9.
33. Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer 2002; 94: 950-63.
34. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low dose aspirin and the incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1220-4.
35. Peleg II, Lubin MF, Costonis GA, Clark WS, Wilcox CM. Long-term use of nonsteroidal anti-inflammatory drugs and other chemopreventors and the risk of subsequent colorectal neoplasia. Dig Dis Sci 1996; 41: 1319-26.
36. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-9.
37. Benamouzig R, Deyra J, Martin A et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology 2003; 125: 328-36.
38. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study. Gastroenterology 2002; 122: 641-5.
39. Giardiello FM, Yang VW, Hylind LM et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346: 1054-9.
40. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthriAis and rheumatoid arthritis: The CLASS study: a randomized controlled trial (Celecoxib Long-term Arthritis Safety Study). J Am Med Assoc 2000; 284: 1247-55.
41. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
42. Rahme E, Barkun AN, Toubouti Y, Bardou M. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 2003; 125: 404-12.
43. Steinback G, Lynch PM, Phillips PKS et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
44. Chu AJ, Chou TH, Chen BD. Prevention of colorectal cancer using COX-2 inhibitors: Basic science and clinical applications. Front Biosci 2004; 9: 2697-713.
45. Hallak A, Alon-Baron L, Shamir R et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003; 48: 1998-2002.
46. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003; 9: 4756-60.
47. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-90.
48. Milas L, Mason KA, Crane CH, Liao Z, Masferrer J. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology (Williston Park) 2003; 17: 15-24.
49. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000; 6: 2513-20.
50. Kishi K, Petersen S, Petersen C et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000; 60: 1326-31.
51. Yamauchi T, Watanabe M, Hasegawa H et al. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. J Natl Cancer Inst 1997; 89: 1152-60.
52. Benedetti AL, Collet JP, Boivin JF, Hanley JA. Effect of nonsteroidal anti-inflammatory drugs on stage of colon cancer at diagnosis. J Clin Epidemiol 2003; 56: 782-7.
53. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 2002; 16: 31-7.
54. Becerra CR, Frenkel EP, Ashfaq R, Gaynor RB. Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. Int J Cancer 2003; 105: 868-72.
55. Victor Trial (2002-2004). Available from: http://www.octo-oxford.org.uk/Trials/victor/victor.aspx. (accessed 15th February 2005)
56. Barnes CJ, Lee M. Determination of an optimal dosing regimen for aspirin chemoprevention of 1,2- dimethylhydrazine-induced colon tumours in rats. Br J Cancer 1999; 79: 1646-50.
57. Ruffin MT 4th, Krishnan K, Rock CL et al. Suppression of human colorectal mucosal prostaglandins: Determining the lowest effective aspirin dose. J Natl Cancer Inst 1997; 89: 1152-60.
58. Vioxx.com. Available at: http://www.vioxx.com/rofecoxib/vioxx/hcp/ hcp_notification_physicians.jsp.
59. Rigas B, Williams JL. NO-releasing NSAIDs and colon cancer chemoprevention: A promising novel approach. Int J Oncol 2002; 20: 885-90.
60. Kaza CS, Kashfi K, Rigas B. Colon cancer prevention with NO-releasing NSAIDs. Prostaglandins Other Lipid Mediat 2002; 67: 107-20.
61. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: A cost-effectiveness analysis. Gastroenterology 2002; 122: 78-84.
62. Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: A cost-effectiveness analysis. Am J Med 2003; 114: 546-54.
63. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: A cost-effectiveness analysis. Ann Intern Med 2001; 135: 769-81.
64. Hegazi RA, Mady HH, Melhem MF, Sepulveda AR, Mohi M, Kandil HM. Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflamm Bowel Dis 2003; 9: 230-6.